Posted in | News

Multi-Engine Design Expected to Deliver Fuel Savings and Environmental Benefits

Wabtec Corporation said its MotivePower subsidiary has introduced a new, ultra low emissions switcher locomotive with a multi-engine design that is expected to deliver fuel savings and other environmental benefits. Known as the MPEx, the locomotive is expected to begin revenue service testing with Class I railroads in the first quarter.

"With the MPEx, MotivePower is building on its experience as a leading manufacturer of low-horsepower locomotives to help railroads reduce emissions and increase efficiency," said Albert J. Neupaver, Wabtec's president and chief executive officer. "This new, ultra low emissions locomotive combines the best features of prior models with enhanced engine technology to offer an environmentally sound solution that is also expected to save fuel, reduce maintenance and improve reliability. With more than 2,500 locomotives delivered since 1972, MotivePower has developed a reputation for quality and innovation, and the MPEx is a worthy addition to its product portfolio."

MotivePower will offer the MPEx in either a three-engine or two-engine design, both of which will be compliant with Tier 3 non road emission levels. The locomotive is expected to produce fuel savings of at least 35 percent, while reducing emissions of NOx by at least 80 percent and particulate matter by at least 70 percent. Other features include an integrated automatic engine start/stop, high-visibility operator's cab, QES-III microprocessor control system and pressurized engine car body. The locomotives will contain a number of components produced by other Wabtec subsidiaries, including the microprocessor control system, braking equipment, brake shoes and radiators.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.